MAGNA Pharmaceuticals Selects LSPediA for DSCSA Serialization

LSPediA, a leading software and service provider for the pharmaceutical industry, today announced a new business relationship with MAGNA Pharmaceuticals.

MAGNA specializes in supplying high-quality prescription and consumer products to health care providers contracted under the U.S. Department of Veterans Affairs and the civilian market. Meeting federal and state compliance requirements is a proud tradition and a non-negotiable commitment for MAGNA.

The 10-year vision of the FDA’s 2013 Drug Supply Chain Security Act enforces new and stringent requirements to strengthen the U.S. drug supply chain and eradicate drug counterfeiting.

“Patient safety is paramount in our mission, in addition to providing efficacious and affordable products/services for patients and other health care stakeholders,” said Warren Lesser, Ph.D., CEO of MAGNA Pharmaceuticals. “Partnering with LSPediA enables DSCSA compliance and augments our supply chain operations. The cloud technology and RF mobile scanners automate our processes to quickly trade and distribute serialized products with 100% accuracy, contributing to overall health care delivery.”

By leveraging RxChain®, MAGNA Pharmaceuticals enables Track and Trace, Serialization, shipment aggregation, and seamless data exchange with trading partners and provides full FDA DSCSA compliance now and for the future.

“Our software is built for companies like MAGNA to advance supply chain and meet compliance,” said Riya Cao, LSPediA CEO. “RxChain®’s Cloud Solution, mobile technology, and best-in-practice workflow serve as a robust serialization platform for MAGNA’s daily operations. When we take on the heavy lifting of compliance and serialization, our customers can focus on their core business and flourish.”

LSPediA, a leading software and service provider for the pharmaceutical industry, today announced a new business relationship with MAGNA Pharmaceuticals.

MAGNA specializes in supplying high-quality prescription and consumer products to health care providers contracted under the U.S. Department of Veterans Affairs and the civilian market. Meeting federal and state compliance requirements is a proud tradition and a non-negotiable commitment for MAGNA.

The 10-year vision of the FDA’s 2013 Drug Supply Chain Security Act enforces new and stringent requirements to strengthen the U.S. drug supply chain and eradicate drug counterfeiting.

“Patient safety is paramount in our mission, in addition to providing efficacious and affordable products/services for patients and other health care stakeholders,” said Warren Lesser, Ph.D., CEO of MAGNA Pharmaceuticals. “Partnering with LSPediA enables DSCSA compliance and augments our supply chain operations. The cloud technology and RF mobile scanners automate our processes to quickly trade and distribute serialized products with 100% accuracy, contributing to overall health care delivery.”

By leveraging RxChain®, MAGNA Pharmaceuticals enables Track and Trace, Serialization, shipment aggregation, and seamless data exchange with trading partners and provides full FDA DSCSA compliance now and for the future.

“Our software is built for companies like MAGNA to advance supply chain and meet compliance,” said Riya Cao, LSPediA CEO. “RxChain®’s Cloud Solution, mobile technology, and best-in-practice workflow serve as a robust serialization platform for MAGNA’s daily operations. When we take on the heavy lifting of compliance and serialization, our customers can focus on their core business and flourish.”